Gene Solutions Representative Presented Breakthrough Research at European Lung Cancer Congress (ELCC) 2025 – Paris

We are proud to announce that Nguyen Van Thien Chi (MSc), researcher at Gene Solutions, represented Vietnam at the ELCC 2025, organized by European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) from March 26–29, 2025, in Paris, France.

His work was honored with the prestigious “Merit Travel Grant” from ESMO, recognizing its outstanding scientific quality and clinical relevance. This marks a significant achievement for both Chi and the advancement of other research at Gene Solutions.

Key highlights of the study “Analytical and Clinical Validation of a Cost-Effective ctDNA-Based Assay for Lung Cancer Detection” include:

+ Cost-effective Sequencing: This study introduces a cost-effective cfDNA-based assay (SPOT-MAS LUNG test) using shallow genome-wide sequencing for lung cancer detection.

+ Addressing the challenge in lung cancer screening: As a minimally invasive test, SPOT-MAS Lung complements LDCT by improving screening uptake, enhancing surveillance strategies for abnormal imaging results, and supporting broader adoption in routine screening programs.

+ Multi-omic Features: The assay captures lung cancer–specific cfDNA signatures by analyzing fragmentomics, nucleosome positioning, end-motif patterns, and copy number aberrations.

+ AI-enhanced Technology: A machine learning model trained on a labeled dataset cohort (99 LC patients, 168 healthy controls) and then being validated on an independent cohort (58 LC patients, 71 controls), had demonstrated robust performance.

+ High Performance: The model demonstrated high accuracy, achieving specificity of 92%, with sensitivities of 94% and 90% in the discovery and validation cohorts, respectively.

+ High Sensitives across all lung cancer stages: The SPOT-MAS Lung test outperformed traditional hotspot mutation assays and the SPOT-MAS multi-cancer assay in sensitivity across all lung cancer stages, with 75% sensitivity in stages I–II, 91% in stage IIIA, and 88% in stages IIIB–IV.

This novel assay offers a cost-effective, non-invasive solution for early lung cancer detection and helps reduce false positives compared to traditional LDCT screening – especially beneficial in developing healthcare settings. We believe this milestone brings us closer to delivering advanced genetic solutions for early cancer detection on a broader scale.

Read the full abstract here: https://www.jto.org/article/S1556-0864(25)00487-3/fulltext

Learn more about SPOT-MAS Lung and how it can help in early lung cancer detection by visiting our website: https://genesolutions.com/our-test/spot-mas-lung